Once-weekly stereotactic radiotherapy for patients with oligometastases

Compliance and preliminary efficacy

Renzo Corvò, Giorgio Lamanna, Stefano Vagge, Liliana Belgioia, Davide Bosetti, Deborah Aloi, Giorgia Timon, Almalina Bacigalupo

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Aims and background. This retrospective analysis reports the outcomes obtained with an original once-weekly stereotactic radiotherapy fractionation given to patients affected by evolving oligometastases from different solid malignancies. Methods. From 2009 to 2011, patients with symptomatic and/or evolving oligometastases were submitted to a median 5-fraction cycle of stereotactic radiotherapy of one fraction per week in order to exploit a radiobiological rationale designed to increase the therapeutic index. Individual fractionation was mainly planned according to patient performance status, oligometastasis size and site, and record of previous irradiation in the same site. Results. Thirty-six patients in stage IV UICC-TNM affected by oligometastases were treated with image-guided intensity-modulated stereotactic tomotherapy with a single weekly radiation. Median age was 70 years (range, 34-89). The median weekly single dose, number of fractions and overall total radiation dose were 7 Gy, 5 fractions and 35 Gy, respectively. Thirty-five (97%) patients completed the treatment schedule. No patient suffered mild or severe radiation-related side effects. Twenty-one (87%) of 24 patients with local pain had complete symptomatic response within 30 days following the end of radiotherapy. Local control assessed at imaging after stereotactic radiotherapy was evidenced in 30 (83%) patients. Median time to response after the end of radiotherapy was 40 days. Conclusions. The original radiotherapy regimen delivering only a single stereotactic dose per week seems to be highly feasible with an interesting high efficacy rate in patients with oligometastases from different solid tumors. Overall, the once-weekly treatment was very compliant in an advanced cancer stage especially for elderly and frail patients.

Original languageEnglish
Pages (from-to)159-163
Number of pages5
JournalTumori
Volume99
Issue number2
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Compliance
Radiotherapy
Radiation
Frail Elderly
Neoplasms
Appointments and Schedules
Therapeutics
Pain

Keywords

  • Oligometastases
  • Onceweekly fractionation
  • Stereotactic radiotherapy
  • Tomotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Once-weekly stereotactic radiotherapy for patients with oligometastases : Compliance and preliminary efficacy. / Corvò, Renzo; Lamanna, Giorgio; Vagge, Stefano; Belgioia, Liliana; Bosetti, Davide; Aloi, Deborah; Timon, Giorgia; Bacigalupo, Almalina.

In: Tumori, Vol. 99, No. 2, 03.2013, p. 159-163.

Research output: Contribution to journalArticle

Corvò, Renzo ; Lamanna, Giorgio ; Vagge, Stefano ; Belgioia, Liliana ; Bosetti, Davide ; Aloi, Deborah ; Timon, Giorgia ; Bacigalupo, Almalina. / Once-weekly stereotactic radiotherapy for patients with oligometastases : Compliance and preliminary efficacy. In: Tumori. 2013 ; Vol. 99, No. 2. pp. 159-163.
@article{9e4f24b8d9fc48e188e4436b0acf2548,
title = "Once-weekly stereotactic radiotherapy for patients with oligometastases: Compliance and preliminary efficacy",
abstract = "Aims and background. This retrospective analysis reports the outcomes obtained with an original once-weekly stereotactic radiotherapy fractionation given to patients affected by evolving oligometastases from different solid malignancies. Methods. From 2009 to 2011, patients with symptomatic and/or evolving oligometastases were submitted to a median 5-fraction cycle of stereotactic radiotherapy of one fraction per week in order to exploit a radiobiological rationale designed to increase the therapeutic index. Individual fractionation was mainly planned according to patient performance status, oligometastasis size and site, and record of previous irradiation in the same site. Results. Thirty-six patients in stage IV UICC-TNM affected by oligometastases were treated with image-guided intensity-modulated stereotactic tomotherapy with a single weekly radiation. Median age was 70 years (range, 34-89). The median weekly single dose, number of fractions and overall total radiation dose were 7 Gy, 5 fractions and 35 Gy, respectively. Thirty-five (97{\%}) patients completed the treatment schedule. No patient suffered mild or severe radiation-related side effects. Twenty-one (87{\%}) of 24 patients with local pain had complete symptomatic response within 30 days following the end of radiotherapy. Local control assessed at imaging after stereotactic radiotherapy was evidenced in 30 (83{\%}) patients. Median time to response after the end of radiotherapy was 40 days. Conclusions. The original radiotherapy regimen delivering only a single stereotactic dose per week seems to be highly feasible with an interesting high efficacy rate in patients with oligometastases from different solid tumors. Overall, the once-weekly treatment was very compliant in an advanced cancer stage especially for elderly and frail patients.",
keywords = "Oligometastases, Onceweekly fractionation, Stereotactic radiotherapy, Tomotherapy",
author = "Renzo Corv{\`o} and Giorgio Lamanna and Stefano Vagge and Liliana Belgioia and Davide Bosetti and Deborah Aloi and Giorgia Timon and Almalina Bacigalupo",
year = "2013",
month = "3",
doi = "10.1700/1283.14186",
language = "English",
volume = "99",
pages = "159--163",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Once-weekly stereotactic radiotherapy for patients with oligometastases

T2 - Compliance and preliminary efficacy

AU - Corvò, Renzo

AU - Lamanna, Giorgio

AU - Vagge, Stefano

AU - Belgioia, Liliana

AU - Bosetti, Davide

AU - Aloi, Deborah

AU - Timon, Giorgia

AU - Bacigalupo, Almalina

PY - 2013/3

Y1 - 2013/3

N2 - Aims and background. This retrospective analysis reports the outcomes obtained with an original once-weekly stereotactic radiotherapy fractionation given to patients affected by evolving oligometastases from different solid malignancies. Methods. From 2009 to 2011, patients with symptomatic and/or evolving oligometastases were submitted to a median 5-fraction cycle of stereotactic radiotherapy of one fraction per week in order to exploit a radiobiological rationale designed to increase the therapeutic index. Individual fractionation was mainly planned according to patient performance status, oligometastasis size and site, and record of previous irradiation in the same site. Results. Thirty-six patients in stage IV UICC-TNM affected by oligometastases were treated with image-guided intensity-modulated stereotactic tomotherapy with a single weekly radiation. Median age was 70 years (range, 34-89). The median weekly single dose, number of fractions and overall total radiation dose were 7 Gy, 5 fractions and 35 Gy, respectively. Thirty-five (97%) patients completed the treatment schedule. No patient suffered mild or severe radiation-related side effects. Twenty-one (87%) of 24 patients with local pain had complete symptomatic response within 30 days following the end of radiotherapy. Local control assessed at imaging after stereotactic radiotherapy was evidenced in 30 (83%) patients. Median time to response after the end of radiotherapy was 40 days. Conclusions. The original radiotherapy regimen delivering only a single stereotactic dose per week seems to be highly feasible with an interesting high efficacy rate in patients with oligometastases from different solid tumors. Overall, the once-weekly treatment was very compliant in an advanced cancer stage especially for elderly and frail patients.

AB - Aims and background. This retrospective analysis reports the outcomes obtained with an original once-weekly stereotactic radiotherapy fractionation given to patients affected by evolving oligometastases from different solid malignancies. Methods. From 2009 to 2011, patients with symptomatic and/or evolving oligometastases were submitted to a median 5-fraction cycle of stereotactic radiotherapy of one fraction per week in order to exploit a radiobiological rationale designed to increase the therapeutic index. Individual fractionation was mainly planned according to patient performance status, oligometastasis size and site, and record of previous irradiation in the same site. Results. Thirty-six patients in stage IV UICC-TNM affected by oligometastases were treated with image-guided intensity-modulated stereotactic tomotherapy with a single weekly radiation. Median age was 70 years (range, 34-89). The median weekly single dose, number of fractions and overall total radiation dose were 7 Gy, 5 fractions and 35 Gy, respectively. Thirty-five (97%) patients completed the treatment schedule. No patient suffered mild or severe radiation-related side effects. Twenty-one (87%) of 24 patients with local pain had complete symptomatic response within 30 days following the end of radiotherapy. Local control assessed at imaging after stereotactic radiotherapy was evidenced in 30 (83%) patients. Median time to response after the end of radiotherapy was 40 days. Conclusions. The original radiotherapy regimen delivering only a single stereotactic dose per week seems to be highly feasible with an interesting high efficacy rate in patients with oligometastases from different solid tumors. Overall, the once-weekly treatment was very compliant in an advanced cancer stage especially for elderly and frail patients.

KW - Oligometastases

KW - Onceweekly fractionation

KW - Stereotactic radiotherapy

KW - Tomotherapy

UR - http://www.scopus.com/inward/record.url?scp=84881250666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881250666&partnerID=8YFLogxK

U2 - 10.1700/1283.14186

DO - 10.1700/1283.14186

M3 - Article

VL - 99

SP - 159

EP - 163

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 2

ER -